2016年，人類細胞圖譜計劃（HumanCell Atlas Project）被提出：根據(jù)*的分子信息（如基因表達）對所有人類細胞種類進行定義，并將這些信息與傳統(tǒng)的細胞學表述（如位置和形態(tài)）相關(guān)聯(lián)，來了解人體中的所有細胞的類型、每個細胞的空間位置、每個細胞在不同生命時刻的狀態(tài)以及不同個體細胞圖譜的疊加，并根據(jù)不同健康狀態(tài)、基因型、生活方式和外界環(huán)境加以注釋。

而傳統(tǒng)的單細胞測序技術(shù)只是對單個細胞進行轉(zhuǎn)錄組學的研究，很難實現(xiàn)大通量單細胞轉(zhuǎn)錄組測序；近年來，單細胞測序技術(shù)獲得快速發(fā)展，尤其是基于微液滴技術(shù)的大規(guī)模單細胞分選平臺的出現(xiàn)，使我們能夠以較低的成本對某一器官或者組織構(gòu)建其細胞表達圖譜，了解各個器官或者組織細胞復雜的基因網(wǎng)絡在單個細胞中的運作機制，并了解各個細胞中這些網(wǎng)絡的差異，以及zui終各種細胞群體如何協(xié)同工作。

2016年2月，10X Genomics公司推出大規(guī)模單細胞轉(zhuǎn)錄組測序系統(tǒng)——Chromium™ Single Cell 3' Solution，可以對高通量的數(shù)字基因表達的復雜細胞群進行深入分析，生命科學研究進入單細胞生物學時代。

作為國內(nèi)*家引進10X Genomics平臺的公司，博奧晶典*推出了Chromium™ SingleCell 3' Solution平臺服務，并完成了人和小鼠的肝臟、肺臟、皮膚、心臟、腦、腎臟、血液，以及植物葉片等多種類型樣本的檢測。

Chromium™ Single Cell 3' Solution是一種在單個細胞水平對mRNA進行高通量測序的新技術(shù)，為單細胞轉(zhuǎn)錄組研究提供更具擴展性的平臺。其基于10X Genomics平臺，一次性能夠分離500~10000個單細胞，并能夠?qū)⒎蛛x的單個細胞中的微量mRNA通過高效擴增后再進行高通量測序，有效地解決了組織樣本無法破解的細胞異質(zhì)性難題，有助于發(fā)現(xiàn)新的細胞類型；并基于大量的單細胞基因表達數(shù)據(jù)，可進行細胞表達特征聚類、亞群表達特征、標志物篩選等方面的分析，是一種高效的細胞基因表達水平的檢測技術(shù)，在生殖、免疫反應、干細胞發(fā)育與分化、腫瘤異質(zhì)性、神經(jīng)系統(tǒng)研究以及腦發(fā)育等研究領域中有著廣泛的應用。

The British "nature" magazine recently "why researchers want to Chinese" as the author said, will overtake the us to become the world's largest investment in R & D Chinese in 2019. In the United States, both the Silicon Valley scientists and the postdoctoral graduate students will feel the impact of the development of China's science and technology.

Raymond Stevens, who has established 3 Biotech Corp at the University of Southern California, is now employed as director of a Research Institute at Shanghai University of science and technology. He believes that Chinese will be the next one to develop the most advanced countries, "from the cultural perspective, China attaches great importance to the development of science and technology, like the Americans like sports, I China on progress of science and technology of the curious, I want my 3 children are China life, looking forward to Chinese provide more opportunities for their day the development of". Today, Stevens works half a year in Shanghai.

The article holds that R & D investment is crucial to the stable development of China. At the same time, China's economic growth rate is slowing down, at the same time, it faces double pressures of rising labor costs and reducing labor force. China's strategy is to invest in funds to support the new format. By the end of 2016, business incubators all over China helped to set up more than 22 million start-ups. According to the McKinsey Co analysis, by 2025, the contribution rate of innovation to China's GDP will be as high as 50%. From designing new semiconductor, chemical products to the daily application of AI, China will rely on its expanding scientists and entrepreneurs to develop new products and put them on the market quickly.

All parts of China are building advanced research and development facilities and increasing the funding for scientific research in Colleges and universities. Investment in human capital is the key to promoting innovation. China is energetically increasing the number of R & D personnel, increasing the number of R & D personnel from 48.5 current 10000 employees to 60.

Although China is still behind the West in some areas of innovation, China's efforts have been fruitful. According to the report of the 2017 global innovation index, China has exceeded Australia in the field of innovation, and the global ranking of innovation has risen to twenty-second. Perhaps more convincing is that in 2016, Chinese college students willing to open their own companies doubled over 2015.

Coincidentally, the American think-tank, the international economic research Pedersen, prior to the "Chinese dragon", "innovation the author said, since the reform and opening up in 1978, Chinese made a hitherto unknown achievement. China's annual average growth rate of 10% is 10%, changing the global trade pattern and becoming the second largest economy in the world. Now, China is facing unprecedented opportunities, that is, to become the "leader of the world" innovation.

The article holds that the foundation of the great changes in China is the unprecedented prosperity of the manufacturing industry. In 2016, China exported more than $2 trillion to all parts of the world, accounting for 13% of the world's total exports. At the same time, China has also promoted economic modernization through large-scale infrastructure investment, including bridges, airports, roads, energy and ecommunications. In less than 10 years, China has built the world's largest high-speed railway system. As of July 2017, the total mileage of China's high speed rail was over 22 thousand kilometers.

Apple Corp CEO Tim Cook recently said: "Chinese is no longer a state that low labor costs for many years ago, cheap labor is the cause of transnational enterprises in china." China's manufacturing forces are now developing high-end production technology and a powerful supply chain network. At the national level, China's planning has established the goal of making China an innovative country by 2020, entering the forefront of innovative countries by 2030, and becoming a "world technological innovation power" by 2050. China is also planning to increase R & D expenditure to 2.5% of GDP.

At the local level, in order to promote innovation, many Chinese municipal governments have set up scientific and technological centers to attract talents. For example, the city of Guangzhou encourages researchers, entrepreneurs and enterprises to settle in the local area. Shenzhen is known as "hardware Silicon Valley", and Shenzhen - Hongkong area has ranked second in the world from the perspective of global innovation cluster development. At the folk level, the business model of Chinese enterprises has changed rapidly and accepted the digital model in an all-round way. Because of the absence of the old system, China has been able to achieve a "curve overtaking" in the fields of digital payment, sharing of economy and e-commerce.

上一篇：軍團菌檢測試劑盒（乳膠凝集法）

下一篇：E2A（19p13）基因斷裂探針

返回列表>>

廣州健侖生物科技有限公司(www.backhome.top) 熱門產(chǎn)品:喹諾酮類檢測試劑盒,西尼羅河檢測試劑,基孔肯雅熱試劑,寨卡檢測試劑,疫病核酸試劑
地址：廣東省廣州市番禺區(qū)石樓鎮(zhèn)清華科技園創(chuàng)啟路63號A2棟101 Email：service@jianlun.com
ICP備：粵ICP備11063766號 GoogleSitemap 技術(shù)支持：化工儀器網(wǎng) 管理登陸返回首頁